Royalty Report: Drugs, Disease, Therapeutic – Collection: 67284

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diagnostic
  • Pharmaceuticals
  • Assay
  • Proteins
  • Respiratory
  • Fibrosis
  • Technical Know How
  • Genome
  • DNA
  • Surgical
  • Instruments
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 67284

License Grant
The company entered into a global collaboration agreement focused on the discovery and worldwide development and commercialization of potentiator and corrector molecules in a potential triple combination therapy for the treatment of CF (Cystic Fibrosis).
License Property
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects approximately 80,000 patients worldwide and approximately 30,000 patients in the United States.  CF is a chronic disease that affects the lungs and digestive system.  CF patients, with significantly impaired quality of life, have an average lifespan approximately 50% shorter than the population average, with the median age of death at 40.  There currently is no cure for CF.  CF patients require lifelong treatment with multiple daily medications, frequent hospitalizations and ultimately lung transplant, which is life-extending but not curative.  CF is caused by a mutation in the gene for the CFTR protein, which results in abnormal transport of chloride across cell membranes.  Transport of chloride is required for effective hydration of epithelial surfaces in many organs of the body.  Normal CFTR channel moves chloride ions to outside of the cell.  Mutant CFTR channel does not move chloride ions, causing sticky mucous to build up on the outside of the cell.  CFTR dysfunction results in dehydration of dependent epithelial surfaces, leading to damage of the affected tissues and subsequent disease, such as lung disease, malabsorption in the intestinal tract and pancreatic insufficiency.
Field of Use
This agreement pertains to the drug industry for the treatment of cystic fibrosis.

IPSCIO Record ID: 256291

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensee, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensor.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensee, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

For patentable inventions, Licensor grants to an exclusive, royalty free worldwide license to its rights in any Joint Invention and any invention made by made by any CFFT employee resulting from the Research Project to research, develop, manufacture, use, sell and import products.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

CFTR is the key protein associated with cystic fibrosis.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.

Cystic fibrosis (CF) is a life-threatening genetic disease that causes fatal lung infections and serious digestive complications. A mutation in the CFTR gene is one of the key factors that ultimately leads to the symptoms, complications and premature mortality in people with cystic fibrosis.

IPSCIO Record ID: 257285

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensor, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensee.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensor, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

With the Interruption License, Licensor grants with respect to the Research Project the Interruption License, which shall become effective solely upon written notice given by Licensee in the event of an Interruption an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Research Project Technology and the Licensor Background Technology necessary to develop, manufacture, have manufactured. use, sell, offer to sell and import Products in the Field.

In the event that Licensor transfers all of or certain of its rights and obligations to develop and commercialize a Product in the Field at any time, the Third Party to which Licensor transfers all or certain rights and obligations to develop and commercialize the Product in the Field shall be subject to the obligations of the Interruption License.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.
Cystic fibrosis (CF) is an inherited disease that causes thickened mucus to form in the lungs, pancreas and other organs. In the lungs, this mucus blocks the airways, causing lung damage and making it hard to breathe.
Pulmonary Disease or lung disease is any problem in the lungs that prevents the lungs from working properly.

IPSCIO Record ID: 383576

License Grant
Licensors, one being a University, grant a non-exclusive license under the Licensed Patents and Technology to make, have made, use, including use in the performance of services for, by or on behalf of its customers, have used, import, market and/or sell, in the Territory, Products designed and marketed solely for use in the Field of Use.

Licensee agrees to mark, and to require Affiliates to mark, Products with the appropriate patent notice as approved by Licensors, when appropriate.

License Property
The University Licensor and the Research Institute of the Hospital for Sick Children of Toronto, Ontario, Canada, have conducted research relating to cystic fibrosis.

Technology shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensors, covering the gene for cystic fibrosis and uses thereof as covered by the claims of U.S. Patents entitled Cystic Fibrosis Gene.

Field of Use
The Field of Use shall refer to the field for which Product(s) may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Product(s) to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.

IPSCIO Record ID: 282819

License Grant
Licensor hereby grants to Licensee a non-exclusive license under the Licensed Patents and Technology to make, have made, use (including use in the performance of services for, by or on behalf of its customers), have used, import, market, and/or sell in the Territory, Products designed and marketed solely for use in the Field of Use.
License Property
Technology, as used in this Agreement, shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensor, covering mutations in the gene for cystic fibrosis and uses thereof as encompassed by the claims of U.S. Patent No. 5,981,178 and U.S. Patent No. 6,001,588 entitled “Introns and Exons of the Cystic Fibrosis Gene and Mutations at Various Positions of the Gene”.

5,981,178 – Methods for screening for mutations at various positions in the introns and exons of the cystic fibrosis gene

6,001,588 – Introns and exons of the cystic fibrosis gene and mutations thereof

Licensed Patent(s) shall mean U.S. Patent No. 5,981,178, U.S. Patent No. 6,001,588 and PCT Patent Application No. PCT/CA91/00009 entitled “Introns and Exons of the Cystic Fibrosis Gene and Mutations at Various Positions of the Gene” and all foreign equivalent patent applications and Patent Cooperation Treaty filings, and all patents issuing therefrom, in which Licensor has or acquires a property interest, the current list of such application. Licensed Patent(s) shall also include any divisional, continuation, reissue, reexamination or extension of the above-described patent applications and resulting patents, along with any extended or restored term, and any confirmation patent, registration patent, or patent of addition.

Field of Use
Field of Use shall refer to the field for which Products may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Products to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.
Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas.

IPSCIO Record ID: 203256

License Grant
The University Licensor grants a non-transferable, non-exclusive license to make, have made, use, import, offer for sale and sell the Licensed Products and the Licensed Services in the United States under the Patent Rights in the Licensed Field from the effective date of this Agreement.
License Property
The licensed property is for CF Mutations in the CFTR Gene and cystic fibrosis genetic markers.

The licensed product is  any material, composition, Licensor marker, nucleic acid sequence, nucleic acid probe, nucleic acid primer, in vitro diagnostic test, and kit containing any or all of the above, or any other product, process or method, the manufacture, use or sale of which would constitute, but for the license granted to Company, an infringement of a claim.

Field of Use
The use is in the field of bio-electric-microfluidic instrumentation/biochip cartridge for cystic fibrosis molecular diagnostic market.

IPSCIO Record ID: 7388

License Grant
The Italian Licensor hereby grants to the Licensee, stockholder, a non-transferable, exclusive (even as to the Licensor) License under the Patents, the Know-How and the Trademark, for the purposes of having made,  and importing the Compound, and having made, storing, handling, using, promoting, distributing, marketing, offering for sale and selling the Product in the territory for use in the Field of Use.
License Property
The Licensee shall have the right to grant subLicenses with the prior written consent of the Licensor.

Bethkis is an inhaled tobramycin-based product approved by the U.S. Food and Drug Administration (the “FDA”) for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Patent
6,987,094; 7,696,178; 7,939,502; 8,168,598

Cystic fibrosis (also known as CF or mucoviscidosis) is a recessive genetic disease affecting most critically the lungs, and also the pancreas, liver, and intestine. It is characterized by abnormal transport of chloride and sodium across epithelium, leading to thick, viscous secretions.

Patents listed in the Orange Book (upon NDA approval)

Field of Use
The exclusive License granted for the purposes of having made and importing the Compound with all necessary regulatory and governmental approvals and registrations, including NDA approvals, that are required by an Agency to market, distribute, promote and sell the Product in the Territory.

IPSCIO Record ID: 204327

License Grant
Swiss Licensor grants to Licensee, under the cystic fibrosis or CF Know-How and the CF Patent Rights
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product in North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product outside of the Territory and outside of North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export Other Products outside of the Territory and to make or have made or to purchase or have purchased Other Products for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export therapeutic products outside of the Field of Use and to make or have made or to purchase or have purchased therapeutic products outside the Field of Use for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export non-therapeutic products and to make or have made or to purchase or have purchased non-therapeutic products for such purposes.
License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 203566

License Grant
The parties entered into to a Research and Development Agreement dated March 10, 1997 relating to EPI-HNE4, an inhibitor of human neutrophil elastase.  The Parties now enter into this Agreement for thecommercialization of the results of the Research and Development Agreement.

Licensor grants the Swiss Licensee an exclusive license with the right to sublicense during the term of this Agreement, under the EPI-HNE Patent Rights, EPIHNE Technology, the cystic fibrosis or CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export CF Product in the Territory and to make or have made or to purchase or have purchased CF Product for such purposes.

Licensor grants exclusive license with the right to sublicense during the term of this Agreement, under the EPIHNE Patent Rights, EPI-HNE Technology, the applicable CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export any Other Product in the Territory and to make or have made or to purchase or have purchased such Other Products for such purposes.

License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 305717

License Grant
The Foundation awarded the Licensee to conduct a feasibility study using high throughput screening for cystic fibrosis targets. The Foundation also selected and provided support for the Company to conduct this high throughput screening with respect to the cystic fibrosis transmembrane conductance regulator (CFTR) target identified by the Foundation.

The parties have been conducting a research program aimed at identification and design of “Potentiator” and “Corrector” compounds, both of which are directed as a principal mode of therapeutic action at modulation of the biological effect of CFTR in different ways and with different anticipated results.

In 2004, the parties executed the Existing Agreement. The Existing Agreement contemplated that during the course of the research program, the Company would select either the Potentiator or the Corrector approach as its Primary Program (to which a majority of resources under the research program would be directed) and the other approach would be designated as an Alternative Program (to which the balance of resources would be directed).

This amendment is with respect to additional funding for the Potentiator Compounds.

License Property
The Foundation conducts research for new therapies.  They expedite the early stages of a drug and bridge the discovery gap between the academic institutions and the pharmaceutical industry.

The research program is aimed at identification and design of Potentiator and Corrector compounds, both of which are directed as a principal mode of therapeutic action at modulation of the biological effect of cystic fibrosis transmembrane conductance regulator (CFTR) in different ways and with different anticipated results.

Field of Use
The field of use is for the treatment of Cystic Fibrosis which is a rare genetic disease that affects the lungs, pancreas, and other organs.

Licensee is a funding company that collaborates with innovators from academic institutions, research hospitals and not-for-profits biotechnology companies to assist with drug research.

IPSCIO Record ID: 193467

License Grant
The Company entered into a services and collaboration agreement with an undisclosed service provider for the treatment of Crigler-Najjar Syndrome related to the Company’s AT342 development program.
License Property
The program is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects.  The gene therapy has powerful potential to treat these diseases through delivery of a functional copy of the affected gene to cells, resulting in production of the normal protein. We have built a compelling portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy, or XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome, or Crigler-Najjar, AT982 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia, or CASQ2-CPVT.
Field of Use
This agreement pertains to the drug industry relating to the treatment of Crigler-Najjar Syndrome.

Crigler–Najjar syndrome or CNS is a rare inherited disorder affecting the metabolism of bilirubin, a chemical formed from the breakdown of the heme in red blood cells.

Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs their ability to function normally.

IPSCIO Record ID: 118195

License Grant
The parties entered into an agreement to obtain worldwide rights to TOBI.
License Property
TOBI, is an inhaled antibiotic that was developed to treat pseudomonal lung infections. TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.  TOBI also is being used by non-CF patients with similar respiratory infections.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 7396

License Grant
The Licensor hereby grants to the Spanish Licensee, during the Term an exclusive, royalty-bearing License, with the right to subLicense, and under the Licensor Technology, to use, import, offer for sale and sell and otherwise fully Commercialize Licensor Products in the territory.
License Property
The Parties desire to establish a collaboration for the development and commercialization of inhaled ciprofloxacin, including the product candidate referred to by Aradigm as ARD-3150, for the treatment of non-cystic fibrosis bronchiectasis.

Intellectual Property includes technology and intellectual property related to inhaled ciprofloxacin. The Licensor and the Licensee desire to establish a collaboration for the development and commercialization of inhaled ciprofloxacin, including the product candidate referred to by the Licensor as ARD-3150, for the treatment of non-cystic fibrosis bronchiectasis.

Cystic fibrosis (also known as CF or mucoviscidosis) is a recessive genetic disease affecting most critically the lungs, and also the pancreas, liver, and intestine. It is characterized by abnormal transport of chloride and sodium across epithelium, leading to thick, viscous secretions.

Patents cover Lipoquin, Free Ciprofloxacin, and Pulmaquin.

Field of Use
The exclusive rights granted apply for the treatment of Non-cystic fibrosis bronchiectasis.  Concurrently with the execution and delivery of this Agreement, the Parties are entering into an option Agreement pursuant to which the Licensor will grant to the Licensee an exclusive option to License Licensor's AERx Pulmonary Drug Delivery System for use with Licensee's alpha-1 antitrypsin – A1AT – molecule.

IPSCIO Record ID: 28236

License Grant
The company entered into a license agreement to obtain worldwide rights to TOBI with a Foundation.
License Property
The drug TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 339531

License Grant
The parties amend certain terms of the original License Agreement in light of the sublicensee agreements.

The First Amendment has been amended to include but not limited to License Product, Regulatory Exclusivity, Sublicensee Royalty Term, Sublicensee Product and Royalty payments.

License Property
Patent applications relates to a novel synthetic microdystrophin gene to make, sell and distribute products for use in the treatment of Duchene and related disease indications resulting from a lack of functional dystrophin.

Licensed Product) is amended by adding (a) Any product, apparatus, kit, composition, or component thereof (i) whose use, sale, offer for sale, or importation of which is covered, in whole or in part, by any valid claim contained in the Patent Rights or (ii) which is made by any method, procedure, process, or step which is covered, in whole or in part, by any valid claim contained in the Patent Rights; or (b) An isolated synthetic nucleic acid molecule comprising a synthetic mini-dystrophin or micro-dystrophin gene encoding a synthetic, non-full-length, dystrophin protein that is able to restore nNOS to the sarcolemma, wherein the non-full-length dystrophin protein comprises, from the N terminus to the C terminus 1. the N-terminal domain of the dystrophin protein or a modified N-terminal domain of the dystrophin protein, 11. at least two repeats of the mid-rod domain of the dystrophin protein, wherein said at least two repeats comprise R16 and Rl 7, 111. at least 2 hinge regions of the dystrophin protein, whereas said at least two hinge regions comprise HI and H4, and 1v. the cysteine-rich domain of the dystrophin protein; wherein the mini- or micro-dystrophin gene is between 5 kb to about 8 kb in length or less than 5 kb in length, respectively.

Duchenne is caused by mutations in the dystrophin gene, which result in the absence or near-absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and tear. Without functioning dystrophin and certain associated proteins, muscles suffer excessive damage from normal daily activities and are unable to regenerate, leading to the build-up of fibrotic, or scar, and fat tissue. Efforts are focused on our lead product candidate, SGT-001, a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patients’ muscles and improve the course of the disease. Based on our preclinical program that included multiple animal species of different phenotypes and genetic variations, as well as preliminary clinical trial biomarker results, we believe that SGT-001, has the potential to slow or even halt the progression of Duchenne, regardless of the type of genetic mutation or stage of the disease.

Sublicensee Product means any Licensed Product commercialized by Sublicensee, its affiliates or permitted sublicensees pursuant to the Collaboration and License Agreement, dated October 22, 2020, by and between Sublicensee and Licensee.

SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy designed to address the underlying genetic cause of Duchenne muscular dystrophy (Duchenne). Duchenne is caused by mutations in the dystrophin gene that result in the absence or near absence of dystrophin protein. SGT-001 is a systemically administered candidate that delivers a synthetic dystrophin gene, called microdystrophin, to the body. This microdystrophin encodes for a functional protein surrogate that is expressed in muscles and stabilizes essential associated proteins, including neuronal nitric oxide synthase (nNOS). Data from Solid’s preclinical program suggests that SGT-001 has the potential to slow or stop the progression of Duchenne, regardless of genetic mutation or disease stage.

Field of Use
Field of use is for the cure Duchenne muscular dystrophy (“Duchenne”), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Duchenne is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births.  SGT-001 is our lead gene transfer candidate and the focus of our research and development efforts. Gene transfer, a type of gene therapy, is designed to address diseases caused by mutated genes through the delivery of functional versions of those genes, called transgenes. The transgenes are then utilized by the body to produce proteins that are absent or not functional prior to treatment, potentially offering long-lasting beneficial clinical effects.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.